FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3016540994> ?p ?o ?g. }

• W3016540994 abstract "Background and Aim: The standard of care for patients with gliomas should follow established guidelines. In real-world management, however, the management sometimes deviates from these guidelines. We organized a discussion of real-world clinical cases and summarized different considerations from Chinese and European specialists.Case Presentation: A multidisciplinary team comprising experts from Europe and China discussed two patients with glioma treated at Sun Yat-sen University Cancer Center and Liaoning Cancer Hospital and Institute, China. Patient 1 was a 43-year-old man with a recurrent oligodendroglioma in the left frontal lobe diagnosed based on histology alone. He had undergone a biopsy and was diagnosed with an oligodendroglioma 3 years previously. He underwent chemoradiotherapy followed by 12 cycles of chemotherapy with temozolomide (TMZ), and complete remission was achieved. However, the tumor recurred within a short period of time and was resected by a second surgery. The pathologic diagnosis of the recurrent tumor was a glioblastoma because 1p/19q was intact when detected by sequencing. Pathologic consultation from another hospital still considered an anaplastic oligodendroglioma based on the positive result of 1p19q loss of heterozygosity (LOH) determined by fluorescence in situ hybridization. Patient 2 was a 50-year-old man with a left temporal glioblastoma. He underwent tumor resection but no radiotherapy. After seven cycles of TMZ (5/28-day regimen), his symptoms deteriorated, and his treatment was changed to a TMZ dose-dense regimen (7 days on/7 days off) and bevacizumab (7.5 mg/kg every 2 weeks), plus tumor-treating field therapy. Consultation Results: The pathological diagnosis based on biopsy for Patient 1 was an oligodendroglioma (World Health Organization Grade II), whereas the result of the second surgical sample was glioblastoma or anaplastic oligodendroglioma (questionable). Although the accuracy of fluorescence in situ hybridization for the detection of 1p/19q LOH requires improvement, 1p/19q LOH is typically not reconstituted in oligodendroglioma. More likely, it was due to sampling; a positive observation field may be missed with consequent negative results, and both oligodendroglioma (with 1p/19q co-deletion and isocitrate dehydrogenase mutation) and astrocytoma (without 1p/19q co-deletion) may exist. With respect to further treatment for cases such as Patient 1, both Chinese and European experts agree that procarbazine + lomustine chemotherapy is appropriate, while re-irradiation is suggested only if the tumor recurs outside the original radiotherapy field or within the radiotherapy field in the future. Considering the medical history, the rapid tumor regrowth without postoperative radiotherapy in Patient 2 was not surprising. After application of a rescue treatment regimen, the general condition of the patient improved, which may have resulted from the bevacizumab. A consensus was reached between the Chinese and European experts regarding subsequent treatment of Patient 2. Continuation of TMZ and bevacizumab was suggested until further deterioration. Whether tumor-treating field therapy should play a role in this patient could not be evaluated. However, some other molecular targeted agents (e.g. vascular endothelial growth factor receptor tyrosine kinase inhibitors such as regorafenib or apatinib) after bevacizumab failure, the effectiveness of these drugs remains unclear. Conclusion: In clinical practice, although we should follow established guidelines, the final treatment regimen requires informed consent from the patient. Thus, some real-world cases may deviate from the established guidelines. When patients reach end-stage disease with a marked decrease in their performance status and no standard treatment options, active antitumor treatment might be more likely to be attempted in China, while symptomatic treatment is more frequently performed in Europe. Although treatment philosophies for patients with glioma are slightly different between Eastern and Western medical experts, any treatment strategies should satisfy these patients." @default.
• W3016540994 created "2020-04-24" @default.
• W3016540994 creator A5006263750 @default.
• W3016540994 creator A5012070999 @default.
• W3016540994 creator A5032455600 @default.
• W3016540994 creator A5032850142 @default.
• W3016540994 creator A5066290988 @default.
• W3016540994 creator A5076451604 @default.
• W3016540994 creator A5082117229 @default.
• W3016540994 creator A5087555162 @default.
• W3016540994 date "2020-01-01" @default.
• W3016540994 modified "2023-10-18" @default.
• W3016540994 title "East meets West for the treatment of glioma: A discussion of real-world cases" @default.
• W3016540994 doi "https://doi.org/10.4103/glioma.glioma_29_19" @default.
• W3016540994 hasPublicationYear "2020" @default.
• W3016540994 type Work @default.
• W3016540994 sameAs 3016540994 @default.
• W3016540994 citedByCount "0" @default.
• W3016540994 crossrefType "journal-article" @default.
• W3016540994 hasAuthorship W3016540994A5006263750 @default.
• W3016540994 hasAuthorship W3016540994A5012070999 @default.
• W3016540994 hasAuthorship W3016540994A5032455600 @default.
• W3016540994 hasAuthorship W3016540994A5032850142 @default.
• W3016540994 hasAuthorship W3016540994A5066290988 @default.
• W3016540994 hasAuthorship W3016540994A5076451604 @default.
• W3016540994 hasAuthorship W3016540994A5082117229 @default.
• W3016540994 hasAuthorship W3016540994A5087555162 @default.
• W3016540994 hasBestOaLocation W30165409941 @default.
• W3016540994 hasConcept C126322002 @default.
• W3016540994 hasConcept C141071460 @default.
• W3016540994 hasConcept C143998085 @default.
• W3016540994 hasConcept C2775934546 @default.
• W3016540994 hasConcept C2776694085 @default.
• W3016540994 hasConcept C2777389519 @default.
• W3016540994 hasConcept C2777802072 @default.
• W3016540994 hasConcept C2777931997 @default.
• W3016540994 hasConcept C2778227246 @default.
• W3016540994 hasConcept C2778424827 @default.
• W3016540994 hasConcept C2778880634 @default.
• W3016540994 hasConcept C2781413609 @default.
• W3016540994 hasConcept C502942594 @default.
• W3016540994 hasConcept C509974204 @default.
• W3016540994 hasConcept C71924100 @default.
• W3016540994 hasConceptScore W3016540994C126322002 @default.
• W3016540994 hasConceptScore W3016540994C141071460 @default.
• W3016540994 hasConceptScore W3016540994C143998085 @default.
• W3016540994 hasConceptScore W3016540994C2775934546 @default.
• W3016540994 hasConceptScore W3016540994C2776694085 @default.
• W3016540994 hasConceptScore W3016540994C2777389519 @default.
• W3016540994 hasConceptScore W3016540994C2777802072 @default.
• W3016540994 hasConceptScore W3016540994C2777931997 @default.
• W3016540994 hasConceptScore W3016540994C2778227246 @default.
• W3016540994 hasConceptScore W3016540994C2778424827 @default.
• W3016540994 hasConceptScore W3016540994C2778880634 @default.
• W3016540994 hasConceptScore W3016540994C2781413609 @default.
• W3016540994 hasConceptScore W3016540994C502942594 @default.
• W3016540994 hasConceptScore W3016540994C509974204 @default.
• W3016540994 hasConceptScore W3016540994C71924100 @default.
• W3016540994 hasLocation W30165409941 @default.
• W3016540994 hasOpenAccess W3016540994 @default.
• W3016540994 hasPrimaryLocation W30165409941 @default.
• W3016540994 hasRelatedWork W16180300 @default.
• W3016540994 hasRelatedWork W18573702 @default.
• W3016540994 hasRelatedWork W18954325 @default.
• W3016540994 hasRelatedWork W21299109 @default.
• W3016540994 hasRelatedWork W21407813 @default.
• W3016540994 hasRelatedWork W22447948 @default.
• W3016540994 hasRelatedWork W3582852 @default.
• W3016540994 hasRelatedWork W547802 @default.
• W3016540994 hasRelatedWork W5806089 @default.
• W3016540994 hasRelatedWork W6961521 @default.
• W3016540994 isParatext "false" @default.
• W3016540994 isRetracted "false" @default.
• W3016540994 magId "3016540994" @default.
• W3016540994 workType "article" @default.